QL Biopharma focuses on innovative drugs for chronic metabolic disorders, building a differentiated pipeline of ultra-long-acting, oral, and multi-target peptides to improve patient compliance. Its lead asset, ZT002 (a once-monthly injectable GLP-1RA), is in Phase III weight-loss trials in China after Phase II data showed 13.8 % weight reduction at 24 weeks with minimal GI-related dropouts. Additional programs include ZT006, an oral GLP-1 receptor agonist in Phase II for obesity, and ZT003, a GLP-1/FGF21 dual agonist in Phase I trials in Australia. The company also licenses its semaglutide biosimilar ZT001 to Tonghua Dongbao and Aimeike for diabetes and weight-management indications. Four in-house technology platforms (QLLong, QLOral, QLFold, and QLFusion) span R&D through commercial-scale production, backed by a recently approved manufacturing facility. Proceeds will accelerate clinical advancement, regulatory filings, and commercialization of its metabolic disease portfolio. No revenue or user metrics were disclosed in the articles.

Total raised

$73M

Funding rounds

2

Latest round

Series C

Latest activity

Mar 2026